`
Monday, 26 June 2017

Drug Discovery News

  • Eisai receives license for new indication for anticancer agent Kisplyx

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 15 Sep, 2016

    TOKYO: Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the European Commission for anticancer agent Kisplyx (generic name: lenv...Read more

  • Singapore develops new protein to alter DNA in living cells

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 14 Sep, 2016

    Singapore: Researchers in Singapore have developed a new protein that can alter DNA in living cells with much higher precision than current methods. The ability to alter DNA accurately wil...Read more

  • Glenmark receives ANDA approval for Nystatin, Triamcinolone Acetonide ointment

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 08 Aug, 2016

    Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Nystatin and Triamcinolone Acetonide Ointment USP, 10...Read more

  • Novogen progresses on drugs against genetic, degenerative disorders

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 14 Nov, 2013

    Singapore: Australian company Novogen, engaged in a pilot program aimed at breakthrough development of drugs to treat a wide range of genetic and non-genetic degenerative diseases, has met ...Read more

  • Glenmark develops first-of-its-kind antibody

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 05 Feb, 2013

    Singapore: Glenmark Pharmaceuticals has started the discovery and initiation of IND enabling studies of a novel clinical development anti-OX40 monoclonal antibody. GBR 830.  The drug cand...Read more

  • Tivozanib shows superiority over sorafenib in trial

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 18 May, 2012

    Singapore: Investigational agent, tivozanib, has demonstrated statistically significant and clinically meaningful PFS superiority versus approved targeted agent sorafenib in advanced Renal ...Read more

  • Pluristem secures Japan's PMDA nod on regenerative drug trial protocol

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 22 Dec, 2015

    Pluristem Therapeutics Inc., Israel's developer of placenta-based cell therapy products, has reached an agreement with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the desig...Read more

  • Bone Medical reveals results of arthritis study

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 30 Jan, 2013

    Singapore: Australia-based Bone Medical, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, revealed its initial findings from a proof-of-...Read more

  • FDA nod for Novartis Cushing's disease drug Signifor

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 08 Nov, 2012

    Singapore: The US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients wit...Read more

  • Chugai gets positive outcome from Actemra Subcutaneous Injection trials

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 17 May, 2016

    Japanese pharmaceutical giant Chugai Pharmaceutical Co Ltd has announced that its Actemra Subcutaneous Injection (Actemra), the humanized antihuman IL-6 receptor monoclonal antibody, succes...Read more

  • Prosetta Biosciences, Takeda to co-discover drugs for neurodegenerative diseases

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 03 May, 2016

    Prosetta Biosciences Inc. has entered into a Feasibility and First Right of Negotiation Agreement with Japan's Takeda Pharmaceutical Company Limited, to conduct a feasibility study for the ...Read more

  • FDA approves Lupin's new generic

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 23 Jun, 2016

    Pharma Major Lupin announced that its US subsidiary, Gavis Pharmaceuticals LLC., (collectively Lupin) has received final approvals for its Voriconazole Tablets, 50 mg & 200 mg and Voric...Read more

  • Gout therapeutics market clocks $988.7 mn in 2011

    Drug Discovery |  Analysis | By BioSpectrum Bureau | 0 Comment | 23 May, 2012

    Singapore: GlobalData's analysis shows that the global gout therapeutics market grew at a compound annual growth rate (CAGR) of 13.4 percent from $527.4m in 2006 to $988.7 mn in 2011, and ...Read more

  • Pfizer, Repligen to push spinal muscular atrophy program

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 07 Jan, 2013

    Singapore: US-based Repligen has entered into an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from...Read more

  • UK commits $1.6 bn to fight AIDS, TB, Malaria

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 24 Sep, 2013

    Singapore: United Kingdom (UK) has committed to contrbute $1.6 billion to fight AIDS, Tuberculosis and Malaria. Ms Justine Greening, Secretary of State for International Development, UK, a...Read more

  • China firm Beigene raises $75 mn

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 18 Nov, 2014

    Singapore: China based biotech firm developing targeted and immune-oncology therapeutics, BeiGene, has raised $75 million from a group of investors. "We currently have three oncology candi...Read more

  • Johns Hopkins releases NCD policy briefs

    Drug Discovery |  Analysis | By BioSpectrum Bureau | 0 Comment | 05 Feb, 2013

    Singapore: Johns Hopkins University's Institute for Applied Economics, Global Health and the Study of Business Enterprise has released a focused set of policy briefs that provide actionable...Read more

  • Suven gets patents for NCE in Canada, China and India

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 04 Feb, 2014

    Bangalore: Suven Life Sciences received three product patents one each from Canada (2600271), China (CN 101544592B) and India (257850) for its new chemical entities (NCEs) for the treatment...Read more

Survey Box

Will Asia- Pacific healthcare IT market hit the double digit growth in the next five years?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls